FR2414915A1 - Medicament a activite prolongee pour le traitement du cancer du sein, constitue d'un melange de 2a-methyl-dihydrotestosterone, de propionate de 2a-methyl-dihydrotestosterone, de capronate de 2a-methyl-dihydrotestosterone et d'heptanoate de 2a-methyl-dihydrotestosterone - Google Patents

Medicament a activite prolongee pour le traitement du cancer du sein, constitue d'un melange de 2a-methyl-dihydrotestosterone, de propionate de 2a-methyl-dihydrotestosterone, de capronate de 2a-methyl-dihydrotestosterone et d'heptanoate de 2a-methyl-dihydrotestosterone

Info

Publication number
FR2414915A1
FR2414915A1 FR7801505A FR7801505A FR2414915A1 FR 2414915 A1 FR2414915 A1 FR 2414915A1 FR 7801505 A FR7801505 A FR 7801505A FR 7801505 A FR7801505 A FR 7801505A FR 2414915 A1 FR2414915 A1 FR 2414915A1
Authority
FR
France
Prior art keywords
acting
long
mammary carcinoma
caproate
propionate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7801505A
Other languages
English (en)
Other versions
FR2414915B1 (fr
Inventor
A M Beskrovny
L N Volovelsky
G V Knorozova
S V Maximov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH I ENDOKRINOLOG
Original Assignee
KH I ENDOKRINOLOG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KH I ENDOKRINOLOG filed Critical KH I ENDOKRINOLOG
Priority to FR7801505A priority Critical patent/FR2414915A1/fr
Publication of FR2414915A1 publication Critical patent/FR2414915A1/fr
Application granted granted Critical
Publication of FR2414915B1 publication Critical patent/FR2414915B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne la médecine. Le médicament faisant l'objet de l'invention est caractérisé en ce qu'il se compose d'un mélange des substances actives suivantes : 2 alpha -méthyl-dihydrotestostérone, le propionate de 2 alpha -méthyl-dihydrotestostérone, le capronate de 2 alpha -méthyl-dihydrotestostérone et l'heptanoate de 2 alpha -méthyl-dihydrotestostérone, lesdites substances répondant à la formule générale :
FR7801505A 1978-01-19 1978-01-19 Medicament a activite prolongee pour le traitement du cancer du sein, constitue d'un melange de 2a-methyl-dihydrotestosterone, de propionate de 2a-methyl-dihydrotestosterone, de capronate de 2a-methyl-dihydrotestosterone et d'heptanoate de 2a-methyl-dihydrotestosterone Granted FR2414915A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7801505A FR2414915A1 (fr) 1978-01-19 1978-01-19 Medicament a activite prolongee pour le traitement du cancer du sein, constitue d'un melange de 2a-methyl-dihydrotestosterone, de propionate de 2a-methyl-dihydrotestosterone, de capronate de 2a-methyl-dihydrotestosterone et d'heptanoate de 2a-methyl-dihydrotestosterone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7801505A FR2414915A1 (fr) 1978-01-19 1978-01-19 Medicament a activite prolongee pour le traitement du cancer du sein, constitue d'un melange de 2a-methyl-dihydrotestosterone, de propionate de 2a-methyl-dihydrotestosterone, de capronate de 2a-methyl-dihydrotestosterone et d'heptanoate de 2a-methyl-dihydrotestosterone

Publications (2)

Publication Number Publication Date
FR2414915A1 true FR2414915A1 (fr) 1979-08-17
FR2414915B1 FR2414915B1 (fr) 1981-06-12

Family

ID=9203649

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7801505A Granted FR2414915A1 (fr) 1978-01-19 1978-01-19 Medicament a activite prolongee pour le traitement du cancer du sein, constitue d'un melange de 2a-methyl-dihydrotestosterone, de propionate de 2a-methyl-dihydrotestosterone, de capronate de 2a-methyl-dihydrotestosterone et d'heptanoate de 2a-methyl-dihydrotestosterone

Country Status (1)

Country Link
FR (1) FR2414915A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118915A (en) * 1959-02-24 1964-01-21 Syntex Corp 2alpha-lower alkyl dihydro testosterone and derivatives thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118915A (en) * 1959-02-24 1964-01-21 Syntex Corp 2alpha-lower alkyl dihydro testosterone and derivatives thereof

Also Published As

Publication number Publication date
FR2414915B1 (fr) 1981-06-12

Similar Documents

Publication Publication Date Title
JPS5225013A (en) Insulin pharmaceutical for nasal administration
JPS5234935A (en) Medicinal composition
JPS51139617A (en) A process for preparing a remedy for intestinal infectious diseases
JPS5228922A (en) Medicine mixture for animals
JPS52108028A (en) Remedies for dysacousis
FR2414915A1 (fr) Medicament a activite prolongee pour le traitement du cancer du sein, constitue d'un melange de 2a-methyl-dihydrotestosterone, de propionate de 2a-methyl-dihydrotestosterone, de capronate de 2a-methyl-dihydrotestosterone et d'heptanoate de 2a-methyl-dihydrotestosterone
JPS5223744A (en) High frequency heating device
JPS5228946A (en) Amino acid infusion
JPS51114748A (en) High-frequency heating apparatus
JPS534648A (en) Apparatus for facial treatment
JPS51126070A (en) Weber treatment equipment
ES454289A1 (es) Un procedimiento de fabricacion de nuevos compuestos quimi- cos derivados de la quinoleina.
JPS51133179A (en) A process for treatment of sludge
JPS5235201A (en) Decoloration and deodorization of beeswax
JPS51139634A (en) A composition for blood pressure regulation
JPS51138219A (en) Evaporating fuel treatment device of automobiles
JPS5221314A (en) Base material for ointments
JPS5236635A (en) Process for preparation of 4-(3'- dimethylaminopropoxy)-meta- phenylen ediamine
JPS51147266A (en) Semiconductor device
JPS5248692A (en) Preparation of homo-pyriimidazole derivatives
JPS51149598A (en) Piezoelectric body material
JPS5210421A (en) A thiadiazoline series germicide
JPS51124860A (en) Bubble separation and treatment apparatus for drainage
JPS51117699A (en) Coin-choking treatment method for coin- treatment machine
JPS5221388A (en) Process for preparing urokinase containing no pyrogens

Legal Events

Date Code Title Description
ST Notification of lapse